US20230112470A1

Use of egfr/her2 tyrosine kinase inhibitors and/or her2/her3 antibodies for the …

University of Texas System

Abstract

Provided herein are methods of selecting cancer patients for treatment with a covalent EGFR/HER2 TKI, a HER2/HER3 targeting antibody, or a combination of a covalent EGFR/HER2 TKI and a HER2/HER3 targeting antibody as well as methods of treating cancer patients so selected. Cancer patients are …

University: University of Texas System
Assignee: Board Of Regents, The University Of Texas System
Inventor: John Heymach
Priority date: January 29, 2020
Filing date: January 29, 2021
Publication date: April 13, 2023
Language: en
PDF source: https://patentimages.storage.googleapis.com/01/20/de/8f586bb44daf73/US20230112470A1.pdf
Metadata fetched: August 29, 2026 00:31